NCT04729062Approved For Marketing不适用
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is aged at least 12 years or older weighing at least 30 kg.
- •A biopsy has confirmed diagnosis of primary C3G or IC-MPGN or patient has a biopsy-proven histologic recurrence in posttransplant.
- •There is evidence of active renal disease, based on at least 1 g/day of proteinuria from 24-hour urine collection or uPCR ≥1 g/g from random urine in native kidney. There is no minimum level of proteinuria for post-transplant recurrence.
- •Patient has a limited response to treatment regimens for C3G/IC-MPGN, and may include:
- •Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and/or sodium-glucose cotransporter-2 inhibitor therapy
- •Other medications that can affect proteinuria (eg, steroids, mycophenolate mofetil, and/or other immunosuppressants that the patient is receiving for treatment of C3G or IC-MPGN)
- •Patient has received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) as per the Advisory Committee on Immunization Practices (ACIP) recommendations for adults or children with complement deficiencies. Vaccination series should be initiated at least 14 days prior to enrollment. If patient disease is severe and requires immediate treatment, administer required vaccine as soon as possible and provide patients with 2 weeks of prophylactic antibiotics.
- •Female patients of childbearing potential, defined as any women who have experienced menarche and who are not permanently sterile or postmenopausal, must have negative blood pregnancy tests at screening (and negative urine pregnancy tests on day 1) and must agree to use protocol-defined methods of contraception from screening through at least 90 days after receiving the last dose of pegcetacoplan.
- •Patients above the legal age of consent, in accordance with local regulations, must be willing and able to provide informed consent. The legally authorized representative of patients under the legal age of consent must be willing and able to provide informed consent; where appropriate, patients under the legal age of consent must also give their assent to participation in the program.
- •Patient is willing and able to self-administer pegcetacoplan or have an identified caregiver who can perform the administration.
- •Patient currently resides in and is a resident of the US.
排除标准
- •C3G/IC-MPGN is secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, a systemic autoimmune disease such as systemic lupus erythematosus, chronic antibody-mediated rejection, or a medication), in the opinion of the treating physician.
- •Patient has current or prior diagnosis of HIV, hepatitis B, or hepatitis C infection or positive serology during screening that is indicative of infection with any of these viruses.
- •Patient's body weight is greater than 100 kg at screening.
- •Patient has hypersensitivity to pegcetacoplan or to any of the excipients.
- •Patient has history of meningococcal disease.
- •Patient has a severe infection (eg, requiring IV antibiotic therapy) within 14 days prior to the first dose of pegcetacoplan.
- •Patient has an absolute neutrophil count less than 1000 cells/mm3 at screening.
- •Patient has other significant renal disease.
- •Based on the investigator's opinion, the patient has significant glomerulosclerosis or interstitial fibrosis on kidney biopsy.
- •Patient is participating in any other investigational drug trial.
- •Patient is a female who is pregnant or who is currently breastfeeding.
- •Patient has the inability to cooperate or has any condition that, in the opinion of the treating physician, creates an undue risk for the patient by participating in the program.
- •There is evidence of ongoing drug or alcohol abuse or dependence, in the opinion of the treating physician.
- •There is the presence or suspicion of severe infection during the screening period (including but not limited to recurrent or chronic infections) that, in the opinion of the treating physician, may place the patient at unacceptable risk by program participation.
- •There is a known or suspected hereditary fructose intolerance.
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral SclerosisSuperoxide Dismutase 1-Amyotropic Lateral SclerosisNCT04972487Biogen
No Longer Available
不适用
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without CataplexyNarcolepsy Without CataplexyNarcolepsy With CataplexyNCT03433131Harmony Biosciences, LLC
Approved For Marketing
不适用
An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell LeukemiaRelapsed/Refractory Hairy Cell LeukemiaNCT03501615AstraZeneca
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC
Approved For Marketing
不适用
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GISTGISTNCT03862885Blueprint Medicines Corporation